EXHIBIT 99

     CAUTIONARY STATEMENTS REGARDING "SAFE HARBOR" PROVISIONS
      OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

The Company is hereby filing a cautionary statement identifying 
important factors that could cause the Company's actual results to 
differ materially from those projected in forward looking statements 
of the Company made by, or on behalf of, the Company.

 	Competitive factors including technological advances attained by 
competitors; patents granted to competitors; new products of 
competitors coming to the market; generic competition as the 
Company's products mature. 

 	Increased pricing pressure both in the United States and abroad 
from managed care buyers, institutions and government agencies.

 	Government laws and regulations affecting domestic and 
international operations including, among other laws and 
regulations, those resulting from healthcare reform initiatives 
at the state and federal level, as well as those relating to 
trade, monetary and fiscal policies, taxes, price controls, and 
possible nationalization.

 	Patent positions can be highly uncertain and patent disputes are 
not unusual.  An adverse result in a patent dispute can preclude 
commercialization of products or negatively impact sales of 
existing products.

 	Uncertainties of the FDA approval process and the regulatory 
approval processes of foreign countries, including, without 
limitation, delays in approval of new products.

 	Difficulties in product development.  Pharmaceutical product 
development is highly uncertain.  Products that appear promising 
in the early phases of development may fail to reach market for 
numerous reasons.  They may be found to be ineffective or to have 
harmful side effects in clinical or pre-clinical testing, they 
may fail to receive the necessary regulatory approvals, they may 
turn out not to be economically feasible because of manufacturing 
costs or other factors or they may be precluded from 
commercialization by the proprietary rights of others.

 	Recalls of pharmaceutical products as a consequence of previously 
unknown side-effects or for other reasons may occur.

 	Significant litigation adverse to the Company.

 	Fluctuations in interest rates and foreign currency exchange     
    rates.